Company Filing History:
2 out of 1,537 
1 out of 4 Years Active: 2023-2025
Title: The Innovative Contributions of Tobias Friederike Nolden
Introduction
Tobias Friederike Nolden is a notable inventor based in Birgitz, Austria. He has made significant contributions to the field of oncolytic viruses, particularly through his innovative patents. With a total of 2 patents, Nolden's work is paving the way for advancements in cancer treatment.
Latest Patents
Nolden's latest patents focus on a recombinant rhabdovirus encoding for CCL21. This invention relates to the development of oncolytic viruses, specifically a recombinant rhabdovirus, such as vesicular stomatitis virus, which encodes for a CCL21 protein in its genome. The invention is directed towards utilizing this recombinant virus in cancer treatment and outlines methods for producing such viruses.
Career Highlights
Throughout his career, Nolden has worked with prominent companies in the biotechnology sector, including Boehringer Ingelheim International GmbH and Viratherapeutics GmbH. His experience in these organizations has contributed to his expertise in the field of viral therapies.
Collaborations
Nolden has collaborated with several professionals in his field, including Philipp Mueller and Klaus Erb. These partnerships have likely enhanced his research and development efforts.
Conclusion
Tobias Friederike Nolden's innovative work in the realm of oncolytic viruses demonstrates his commitment to advancing cancer treatment. His patents and collaborations reflect a dedication to scientific progress and the potential for impactful medical solutions.